Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Janssen Scientific Affairs, LLC, and Pharmacyclics LLC, an AbbVie Company; and Seagen Inc.
Mentors in Medicine Series on Applied Precision Medicine: Focus on R-CHOP in Lymphoma
Live, Interactive Virtual Webcast!
7:30 PM - 9:00 PM EST
Register and submit a patient case today!
Mentors in Medicine Series on Applied Precision Medicine: Focus on R-CHOP in Lymphoma is a CME-certified, case-based, live webcast. This educational activity will provide practicing oncologists with expert perspectives on incorporating biomarker testing into everyday clinical practice to determine diagnosis and inform treatment selection for their patients with non-Hodgkin lymphoma. Renowned faculty will analyze recent clinical trial evidence to optimize therapeutic strategies, using real patient cases as a starting point. Each case will include an expert analysis of Show Me the Data® as well as Key Takeaways 4 Tomorrow that can be applied immediately in the oncology clinical practice.
Benefits of Attending
- Ask world-renowned experts in hematology and oncology your important clinical questions
- Apply state-of-the-art therapies and strategies into your practice
- Gain expert perspectives and clarity on areas of clinical uncertainty and controversy
- Improve the evidence-based, patient-centered care you provide to your patients
This educational program is intended for hematologists and oncologists involved in the treatment of patients with non-Hodgkin lymphoma. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of non-Hodgkin lymphoma are also invited to attend.
Upon completion of this activity, participants will be able to:
- Incorporate biomarker testing into diagnosis and/or therapy selection for treatment of patients with non-Hodgkin lymphoma
- Analyze recent data on the efficacy and safety of therapeutic options for the treatment of patients with non-Hodgkin lymphoma
- Apply optimal management strategies in the treatment of patients with non-Hodgkin lymphoma based on recent clinical trial findings
- Use of R-CHOP therapy in follicular, mantle cell, and diffuse large B-cell lymphomas
- Management of adverse events associated with R-CHOP therapy
- Deciding when patients need more than R-CHOP Emerging novel combinations for frontline treatment of non-Hodgkin lymphoma
Series Chair & Moderator
Physician-in-Chief, Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer, John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology, Hackensack Meridian School of Medicine
Professor of Medicine, Georgetown University
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventative measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, or I have been in close contact with anyone that has been diagnosed with COVID-19, then I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.